Kelun Biotech announced projections indicating a 112% surge in commercialization revenue by the first half of 2026, according to a company presentation. The anticipated growth reflects increased sales from its expanding portfolio of approved pharmaceutical products and accelerated market penetration.
The biotechnology company highlighted its pipeline progress and commercial strategy as key drivers behind the revenue acceleration. Analysts noted that the projected surge could position Kelun Biotech as a significant player in the biopharmaceutical sector, contingent on execution and market conditions.
The presentation, scheduled for H1 2026, is expected to provide further details on revenue breakdowns, product performance, and strategic initiatives. Kelun Biotech did not disclose specific revenue figures or product names in the announcement.
